KOBV-Portal

Treffer pro Seite

Treffer 1 - 1 | 1 Treffer

Alles auswählen Exportieren

Online-Ressource

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Döhner, Hartmut ; Lübbert, Michael ; Fiedler, Walter ; [weitere]

American Society of Hematology ; 2014

In: Blood Vol. 124, No. 9 ( 2014-08-28), p. 1426-1433

zur Merkliste hinzufügen auf der Merkliste

Details

In: Blood, American Society of Hematology, Vol. 124, No. 9 ( 2014-08-28), p. 1426-1433

Kurzfassung: Volasertib plus low-dose cytarabine increased the response rate and improved survival in AML patients ineligible for intensive treatment. Volasertib plus low-dose cytarabine resulted in responses across all AML genetic subgroups and had a clinically manageable safety profile.

Materialart: Online-Ressource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2014-03-560557

RVK:

XA 33000

RVK:

XA 10000

Sprache: Englisch

Verlag: American Society of Hematology

Publikationsdatum: 2014

ZDB Id: 1468538-3